BACKGROUND: A few studies have investigated the outcome of palliative total gastrectomy (PTG) in stage IV proximal gastric cancer. In this study, we tried to summarize the outcome of PTG in stage IV proximal gastric cancer. METHODS: Between January 1991 and January 2005, complete clinical data of 197 patients with stage IV proximal gastric cancer undergoing PTG, 642 patients undergoing curative total gastrectomy (CTG), 152 nonsurgical patients, 102 patients undergoing explorative laparotomy, and 78 patients undergoing jejunostomy were enrolled in this study. Survival rates, median survival, complication rates, and mortality were analyzed. RESULTS: The 1-year, 3-year, and 5-year survival rates were 61.3%, 8.9%, and 6.4% in the PTG group, respectively, and 92.3%, 58.5%, and 48.9% in the CTG group, respectively (P < .05). The median survival periods in the PTG, no surgery, laparotomy, and jejunostomy groups were 16.4, 5.5, 4.7, and 5.8 months, respectively. The median survival in the PTG group was significantly longer than that in the other 3 groups (P < .05). The postoperative complication rate and mortality rate were, respectively, 24.3% and 3.0% in the PTG group and 13.5% and 2.3% in the CTG group (P > .05). CONCLUSIONS: PTG for stage IV proximal gastric cancer when compared with no surgery, laparotomy, and jejunostomy is associated with prolonged survival time and improved quality of life. However, despite the feasibility and safety of PTG, patients with stage IV proximal gastric cancer who are suitable for this treatment should be selected, and thoughtful preparation should be made in the perioperative period. Crown
BACKGROUND: A few studies have investigated the outcome of palliative total gastrectomy (PTG) in stage IV proximal gastric cancer. In this study, we tried to summarize the outcome of PTG in stage IV proximal gastric cancer. METHODS: Between January 1991 and January 2005, complete clinical data of 197 patients with stage IV proximal gastric cancer undergoing PTG, 642 patients undergoing curative total gastrectomy (CTG), 152 nonsurgical patients, 102 patients undergoing explorative laparotomy, and 78 patients undergoing jejunostomy were enrolled in this study. Survival rates, median survival, complication rates, and mortality were analyzed. RESULTS: The 1-year, 3-year, and 5-year survival rates were 61.3%, 8.9%, and 6.4% in the PTG group, respectively, and 92.3%, 58.5%, and 48.9% in the CTG group, respectively (P < .05). The median survival periods in the PTG, no surgery, laparotomy, and jejunostomy groups were 16.4, 5.5, 4.7, and 5.8 months, respectively. The median survival in the PTG group was significantly longer than that in the other 3 groups (P < .05). The postoperative complication rate and mortality rate were, respectively, 24.3% and 3.0% in the PTG group and 13.5% and 2.3% in the CTG group (P > .05). CONCLUSIONS:PTG for stage IV proximal gastric cancer when compared with no surgery, laparotomy, and jejunostomy is associated with prolonged survival time and improved quality of life. However, despite the feasibility and safety of PTG, patients with stage IV proximal gastric cancer who are suitable for this treatment should be selected, and thoughtful preparation should be made in the perioperative period. Crown
Authors: Tatyana V Khorobrykh; Nuriddin M Abdulkhakimov; Vadim G Agadzhanov; Davit L Aghayan; Airazat M Kazaryan Journal: World J Surg Oncol Date: 2022-06-25 Impact factor: 3.253
Authors: Hyun Beak Shin; Seung Hyoung Lee; Young Gil Son; Seung Wan Ryu; Soo Sang Sohn Journal: World J Surg Oncol Date: 2015-01-30 Impact factor: 2.754
Authors: Chang Min Lee; In Keun Choi; Jong-Han Kim; Da Won Park; Jun Suk Kim; Seong-Heum Park Journal: Ann Surg Treat Res Date: 2016-12-30 Impact factor: 1.859
Authors: Jeremy Tey; Huili Zheng; Yu Y Soon; Cheng N Leong; Wee Y Koh; Keith Lim; Jimmy B Y So; Asim Shabbir; Ivan W K Tham; Jiade Lu Journal: Cancer Med Date: 2019-02-20 Impact factor: 4.452
Authors: Lei Huang; Lina Jansen; Rob H A Verhoeven; Jelle P Ruurda; Liesbet Van Eycken; Harlinde De Schutter; Jan Johansson; Mats Lindblad; Tom B Johannesen; Vesna Zadnik; Tina Žagar; Margit Mägi; Sjoerd M Lagarde; Esther Bastiaannet; Cornelis J H van de Velde; Petra Schrotz-King; Hermann Brenner Journal: Ther Adv Med Oncol Date: 2021-06-28 Impact factor: 8.168